鲁西化工(000830)公司半年报点评



000830 CH Luxi Chemical Group Rating: OUTPERFORM Target Price: Rmb16

Wei Liu wei.liu@htisec.com

Weirong Sun wr.sun@htisec.com

Huaichao Zhuang hc.zhuang@htisec.com

本研究报告由海通国际分销,海通国际是由海通国际研究有限公司,海通国际研究有限公司,海通国际群式会社和海通国际证券集团其他各成员单位的证券研究团队,海通国际证券等团人,海通国际证券活动。关于海通国际的分析师证明,重要披露声明和免责声明,请参阅附录。(Please see appendix for English translation of the disclaimer)

24年上半年扣非归母净利润同比增长588.74%, 看好新项目投产的成长空间

投资要点:

- **鲁西化工公布 2024年半年报**。2024年上半年公司实现营业收入 140.41亿元, 同比增长 21.63%, 实现扣非归母净利润 12.06 亿元, 同比增长 588.74%。
- 公司 2024 年上半年业绩增长主要系部分产品售价同比有所上涨以及原材物料采购价格同比下降,影响部分产品毛利增加。1)分产品看,2024 年上半年化工新材料产品、基础化工产品、化肥产品、其他产品营业收入分别同比变化42.93%、-15.71%、9.50%、18.16%至95.11、28.19、14.52、2.58 亿元;毛利率分别同比变化14.85、-6.24、1.19、6.89个百分点至21.20%、13.33%、7.42%、10.00%。2)2024上半年公司销售毛利率和销售净利率分别为17.99%、8.34%,同比增加7.88、6.66个pct。3)公司2024上半年三项费用率为6.44%,同比减少0.72pct,其中销售、管理(含研发)、财务费用率分别同比减少0.02、0.04、0.66个pct至0.16%、5.69%、0.59%;财务费用的下降主要系有息负债规模以及利率下降所致。
- 公司积极推进项目建设,产能有望进一步提升。2024年上半年公司在建项目包括己内酰胺-尼龙6一期工程、双氧水项目、聚碳酸酯项目、有机硅项目、粉末涂料添加剂项目、化水扩建改造项目、废水零排放扩建项目、24万吨/年乙烯下游一体化项目(二期工程)、15万吨/年丙酸项目,截至2024年上半年项目进度分别为95%、90%、98.5%、90%、96%、97%、95%、50%、40%。
- 公司大宗原料采购注重性价比。化工产品主要原材料为煤炭、丙烯、纯苯、甲醇等,重点与大型国有生产企业稳定合作,稳定渠道,争取价格优势;同时充分利用省内周边炼油企业运距短的优势,就近采购,在确保企业生产需要的同时,有效降低生产成本。装备制造业务的原材料选择与大型供应商和钢厂合作的采购模式,保证供应,提高本质安全,降低成本。
- 盈利预测与参考评级。我们预计 2024-2026 年公司 EPS 分别为 1.00、1.19、1.40 元,参考同行业可比公司估值,我们认为合理的估值为 2024 年 16 倍 PE, 对应目标价 16.00 元,给予"优于大市"评级。
- 风险提示。在建项目进度低于预期,原材料市场价格波动。

主要财务数据及预测

	2022	2023	2024E	2025E	2026E
营业收入 (百万元)	30357	25358	29330	32610	35584
(+/-)YoY(%)	-4.5%	-16.5%	15.7%	11.2%	9.1%
净利润 (百万元)	3155	819	1916	2274	2677
(+/-)YoY(%)	-31.7%	-74.1%	134.0%	18.7%	17.7%
全面摊薄 EPS(元)	1.65	0.43	1.00	1.19	1.40
毛利率(%)	20.0%	13.4%	15.9%	16.4%	16.9%
净资产收益率(%)	18.2%	4.8%	10.4%	11.2%	11.8%

资料来源:公司年报(2022-2023), HTI 备注:净利润为归属母公司所有者的净利润



盈利假设:

销量假设:根据公司 2024 年半年报、项目投资公告和鲁西化工吸收合并鲁西集团 暨关联交易报告书(草案),我们预计己内酰胺尼龙 6 项目 60 万吨在建产能,聚碳酸酯项目 13.5 万吨在建产能将于 2024 年投产,我们预计 2024-2026 年己内酰胺的销量为 44.92、48.13、51.34 万吨,尼龙 6 销量分别为 34.87、45.33、55.79 万吨,聚碳酸酯销量分别为 29.09、30.91、32.73 万吨。根据公司 2023 年年报,双氧水装置在发生事故后处于停产状态,截至 2024 年 8 月公司尚未发布恢复生产公告。我们预计 2024-2026 年,双氧水销量为 31.68、79.20、142.56 万吨。

表 1 鲁西化工分业务盈利预测				
项目	2023	2024E	2025E	2026E
总收入(百万元)	25357.79	29330.43	32610.01	35583.99
总成本 (百万元)	21948.47	24668.21	27257.16	29564.83
总毛利 (百万元)	3409.32	4662.23	5352.85	6019.16
总毛利率	13.44%	15.90%	16.41%	16.92%
化工品(包括化工新材料和基础化工产品)				
收入(百万元)	22316.86	26159.45	29302.47	32133.06
成本 (百万元)	19113.33	21712.34	24174.54	26349.11
毛利 (百万元)	3203.53	4447.11	5127.93	5783.95
毛利率	14.35%	17.00%	17.50%	18.00%
化肥贸易				
收入(百万元)	2601.08	2731.13	2867.69	3011.07
成本 (百万元)	2414.46	2535.19	2661.95	2795.04
毛利 (百万元)	186.61	195.94	205.74	216.03
毛利率	7.17%	7.17%	7.17%	7.17%
其他产品				
收入(百万元)	439.85	439.85	439.85	439.85
成本 (百万元)	420.68	420.68	420.68	420.68
毛利 (百万元)	19.18	19.18	19.18	19.18
毛利率	4.36%	4.36%	4.36%	4.36%

资料来源: Wind, 公司 2023 年年报, HTI

				EPS(元/股)			PE(倍)	
公司名称	股票代码	股价(元)	2023	2024E	2025E	2023	2024E	2025E
华鲁恒升	600426.SH	22.35	1.68	2.18	2.61	13.30	10.25	8.56
三友化工	600409.SH	4.87	0.27	0.35	0.45	18.04	13.91	10.82
	平均值					15.67	12.08	9.69

资料来源: WIND, HTI, 股价为 2024 年 9 月 5 日收盘价, 每股收益均为 WIND 一致预期。



财务报表分析和预测

主要财务指标	2023	2024E	2025E	2026E	利润表 (百万元)	2023	2024E	2025E	2026E
每股指标 (元)					营业总收入	25358	29330	32610	35584
每股收益	0.43	1.00	1.19	1.40	营业成本	21948	24668	27257	29565
每股净资产	8.82	9.64	10.63	11.83	毛利率%	13.4%	15.9%	16.4%	16.9%
每股经营现金流	2.02	1.63	2.15	2.85	营业税金及附加	192	223	248	270
每股股利	0.13	0.20	0.20	0.20	营业税金率%	0.8%	0.8%	0.8%	0.8%
价值评估 (倍)					营业费用	48	56	62	68
P/E	24.15	10.32	8.69	7.39	营业费用率%	0.2%	0.2%	0.2%	0.2%
P/B	1.17	1.07	0.97	0.87	管理费用	597	601	636	694
P/S	0.78	0.67	0.61	0.56	管理费用率%	2.4%	2.1%	2.0%	2.0%
EV/EBITDA	8.28	7.04	6.42	5.53	EBIT	1655	2892	3420	3912
股息率%	1.3%	1.9%	1.9%	1.9%	财务费用	251	436	505	480
盈利能力指标(%)					财务费用率%	1.0%	1.5%	1.5%	1.3%
毛利率	13.4%	15.9%	16.4%	16.9%	资产减值损失	-427	0	0	0
净利润率	3.2%	6.5%	7.0%	7.5%	投资收益	3	3	3	4
净资产收益率	4.8%	10.4%	11.2%	11.8%	营业利润	1133	2481	2940	3457
资产回报率	2.3%	4.7%	5.2%	6.1%	营业外收支	-80	-25	-25	-25
投资回报率	4.2%	6.2%	6.8%	7.9%	利润总额	1053	2456	2915	3432
盈利增长(%)					EBITDA	3966	5212	5817	6291
营业收入增长率	-16.5%	15.7%	11.2%	9.1%	所得税	233	540	641	755
EBIT 增长率	-60.5%	74.8%	18.3%	14.4%	有效所得税率%	22.2%	22.0%	22.0%	22.0%
净利润增长率	-74.1%	134.0%	18.7%	17.7%	少数股东损益	1	0	0	0
偿债能力指标					归属母公司所有者净利润	819	1916	2274	2677
资产负债率	51.8%	54.3%	53.2%	48.0%	2 Sed (4) Se (4) 14 sed (4) (4)				
流动比率	0.18	0.29	0.39	0.48					
速动比率	0.03	0.12	0.17	0.21	资产负债表 (百万元)	2023	2024E	2025E	2026E
现金比率	0.03	0.04	0.07	0.08	货币资金	394	688	1037	1092
经营效率指标					应收账款及应收票据	35	106	127	138
应收账款周转天数	0.69	0.86	1.28	1.34	存货	1597	1850	2650	2874
存货周转天数	26.84	25.15	29.72	33.63	其它流动资产	453	1864	2320	2511
总资产周转率	0.73	0.77	0.77	0.81	流动资产合计	2479	4508	6134	6616
固定资产周转率	1.22	1.33	1.30	1.36	长期股权投资	47	47	47	47
					固定资产	20020	24170	26149	26006
					在建工程	7456	6059	5081	4396
					无形资产	2322	2762	3202	3642
	2023	2024E	2025E	2026E	非流动资产合计	32804	36047	37488	37100
净利润	819	1916	2274	2677	资产总计	35282	40555	43622	43715
少数股东损益	1	0	0	0	短期借款	8256	9256	9256	6756
非现金支出	2733	2320	2396	2379	应付票据及应付账款	1748	1358	1325	1437
非经营收益	127	406	540	523	应 · · · · · · · · · · · · · · · · · · ·	0	0	0	1437
营运资金变动	185	-1528	-1102	-128	其它流动负债	3876	5075	5283	5470
经营活动现金流	3865	3114	4109	5450	流动负债合计	13880	15689	15864	13663
经官伯列况重肌 资产	-3432	-5539	-3862	-2016		······		·····	
					长期借款	2272	4272	5272	5272
投资	0 4	0 -8	0 3	0	其它长期负债非法动负债人计	2108 4380	2051 6323	2051 7323	2051 7323
其他				4 2012	非流动负债合计	· · · · · · · · · · · · · · · · · · ·		·····	
投资活动现金流	- 3428	- 5546	- 3859	- 2012	负债总计	18260	22013	23188	20986
债权募资	1361	3602	1000	-2500	实收资本	1916	1910	1910	1910
股权募资	24	-43	0	0	归属于母公司所有者权益	16896	18416	20308	22603
其他	-1720	-841	-901	-883	少数股东权益	127	127	127	127
融资活动现金流	-336	2717	99	-3383	负债和所有者权益合计	35282	40555	43622	43715
现金净流量	108	294	349	55					

备注: (1) 表中计算估值指标的收盘价日期为 09 月 05 日; (2) 以上各表均为简表

资料来源:公司年报(2023), HTI



APPENDIX 1

Summary

Investment Highlights:

Luxi Chemical Group released its 2024 semi-annual report. In the first half of 2024, the company achieved revenue of RMB 14.04 billion, a YoY increase of 21.63%, and recurring NPAtS of RMB 1.21 billion, a YoY increase of 588.74%. The grow th was mainly due to higher product prices and lower raw material costs, increasing gross profit. 1) By product, revenue changes were: new chemical materials 42.93% to RMB 9.51 billion, basic chemicals -15.71% to RMB 2.82 billion, fertilizers 9.50% to RMB 1.45 billion, and others 18.16% to RMB 0.26 billion. GPM changes were: new chemical materials 14.85 percentage points to 21.20%, basic chemicals -6.24 percentage points to 13.33%, fertilizers 1.19 percentage points to 7.42%, and others 6.89 percentage points to 10.00%. 2) In H1 2024, the company's GPM and NPM were 17.99% and 8.34%, up 7.88 and 6.66 percentage points YoY. 3) The company's expense ratio was 6.44%, down 0.72 percentage points YoY, with sales, management (including R&D), and finance expenses down 0.02, 0.04, and 0.66 percentage points to 0.16%, 5.69%, and 0.59%. The decrease in finance expenses was due to lower interest-bearing debt and interest rates. The company is actively advancing project construction, expecting further capacity increases. H1 2024 projects include caprolactam-nylon 6, hydrogen peroxide, polycarbonate, organosilicon, powder coating additives, water treatment expansion, zero wastewater discharge, 240,000 tons/year ethylene downstream integration (phase II), and 150,000 tons/year propionic acid, with progress at 95%, 90%, 98.5%, 90%, 96%, 97%, 95%, 50%, and 40%. The company focuses on cost-effective bulk raw material procurement, mainly coal, propylene, benzene, and methanol, collaborating with large state-owned enterprises for stable channels and price advantages, and leveraging nearby refineries to reduce costs. Equipment manufacturing raw materials are sourced from large suppliers and steel mills to ensure supply, safety, and cost reduction. Profit forecast and rating: We estimate the company's EPS for 2024-2026 to be RMB 1.00, 1.19, and 1.40. Based on comparable industry valuations, we consider a reasonable valuation to be 16x PE for 2024, with a target price of RMB 16.00, giving an "Outperform" rating.

Risk Warning: Project progress may be slower than expected, and raw material price fluctuations.

附录 APPENDIX

重要信息披露

本研究报告由海通国际分销,海通国际是由海通国际研究有限公司(HTIRL),Haitong Securities India Private Limited (HSIPL),Haitong International Japan K. 司(HTISCL)的证券研究团队所组成的全球品牌,海通国际证券集团(HTISG)各成员分别在其许可的司法管辖区内从事证券活动。

IMPORTANT DISCLOSURES This research report is distributed by Haitong International, a global brand name for the equity research teams of Haitong International Research Limited ("HTIRI Limited ("HSIPL"), Haitong International Japan K.K. ("HTIJKK"), Haitong International Securities Company Limited ("HTISCL"), and any other members within the Hai

of Companies ("HTISG"), each authorized to engage in securities activities in its respective jurisdiction. HTIRL 分析师认证 Analyst Certification:

我,刘威,在此保证(j)本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点,并且(ji)我的报酬中》 的具体建议或观点直接或间接相关:及就此报告中所讨论目标公司的证券,我们(包括我们的家属)在其中均不持有任何财务利益。我和我的家属(判 报告发布后的 3 个工作日内交易此研究报告所讨论目标公司的证券。I, Wei Liu, certify that (i) the views expressed in this research report accurately reflect m the subject companies or issuers referred to in this research and (ii) no part of my compensation was, is or will be directly or indirectly related to the specific rec in this research report; and that I (including members of my household) have no financial interest in the security or securities of the subject companies discussed already notified of this, will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is published.

我, 孙维容,在此保证(i)本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点,并且(ii)我的报酬。 达的具体建议或观点直接或间接相关: 及就此报告中所讨论目标公司的证券,我们(包括我们的家属)在其中均不持有任何财务利益。我和我的家属 究报告发布后的 3 个工作日内交易此研究报告所讨论目标公司的证券。I, Weirong Sun , certify that (i) the views expressed in this research report accurately r or all of the subject companies or issuers referred to in this research and (ii) no part of my compensation was, is or will be directly or indirectly related to the

expressed in this research report; and that I (including members of my household) have no financial interest in the security or securities of the subject compared to the security of securities of the subject compared to the security of securities of the subject compared to the security of securities of the subject compared to the security of securities of the subject compared to the security of securities of the subject compared to the security of securities of the subject compared to the security of securities of the subject compared to the securities of the security of securities of the security of securities of the security of securities of the secu whom I have already notified of this, will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is 我,庄怀起,在此保证(i) 本研究报告中的意见准确反映了我们对本研究中提及的任何或所有目标公司或上市公司的个人观点,并且(ii) 我的报酬。

达的具体建议或观点直接或间接相关: 及就此报告中所讨论目标公司的证券,我们(包括我们的家属)在其中均不持有任何财务利益。我和我的家属 究报告发布后的 3 个工作日内交易此研究报告所讨论目标公司的证券。I. Huaichao Zhuang. certify that (i) the views expressed in this research report accurat any or all of the subject companies or issuers referred to in this research and (ii) no part of my compensation was, is or will be directly or indirectly related to the

whom I have already notified of this, will not deal in or trade any securities in respect of the issuer that I review within 3 business days after the research report is

expressed in this research report; and that I (including members of my household) have no financial interest in the security or securities of the subject compar

利益冲突披露 Conflict of Interest Disclosures 海通国际及其某些关联公司可从事投资银行业务和/或对本研究中的特定股票或公司进行做市或持有自营头寸。就本研究报告而言,以下是有关该等关

证及时无遗漏,如需了解及时全面信息,请发邮件至 ERD-Disclosure@htisec.com) HTI and some of its affiliates may engage in investment banking and / or serve as a market maker or hold proprietary trading position s of certain stocks or comp as this research report is concerned, the following are the disclosure matters related to such relationship (As the following disclosure does not ensure timeliness email to ERD-Disclosure@htisec.com if timely and comprehensive information is needed).

No Disclosure

评级定义(从2020年7月1日开始执行):

海通国际(以下简称"HTI")采用相对评级系统来为投资者推荐我们覆盖的公 司:优于大市、中性或弱于大市。投资者应仔细阅读HTI的评级定义。并且HTI 发布分析师观点的完整信息, 投资者应仔细阅读全文而非仅看评级。在任何情 况下,分析师的评级和研究都不能作为投资建议。投资者的买卖股票的决策应

分析师股票评级

下 中性, 未来 12-18 个月内预期相对基准指数变化不大, 基准定义如下。根据 EINDA/AIVCE 的证如公布规则 我们人怪由此证如别为持右过一米别

优于大市、未来 12-18 个月内预期相对基准指数涨幅在 10%以上,基准定义如

基于各自情况(比如投资者的现有持仓)以及其他因素。

评级分布 Rating Distribution

Neutral, or Underperform for recommending the stocks we cover to investors. Investors should carefully read the definitions of all ratings used in Haitong International Research. In addition, since Haitong International Research contains more complete information concerning the analyst's views, investors should carefully read Haitong International Research, in its

entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other


considerations. **Analyst Stock Ratings**


Outperform: The stock's total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark, as


indicated below. **Neutral:** The stock's total return over the next 12-18 months is expected to be in line with the return of its relevant broad market benchmark, as

indicated below. For purposes only of FINRA/NYSE ratings distribution rules, our Neutral rating falls into a hold rating category. **Underperform:** The stock's total return over the next 12-18 months is expected to be below the return of its relevant broad market benchmark,

as indicated below. Benchmarks for each stock's listed region are as follows: Japan - TOPIX, Korea - KOSPI, Taiwan - TAIEX, India - Nifty100, US - SP500; for all other







Prio

Underperform

0.8%

截至 2024年 6月	30日海通国际股票研究评级分布

China-concept stocks - MSCI China.

	10 1 10 1	1 1	44 4 75 1
		(持有)	
海通国际股票研究覆盖率	91.4%	8.1%	0.6%
投资银行客户*	3.1%	4.8%	0.0%
*在每个评级类别里投资银行客户所。	占的百分比。		

优干大市

上述分布中的买入, 中性和卖出分别对应我们当前优于大市, 中性和落后大市评级。 只有根据 FINRA/NYSE 的评级分布规则,我们才将中性评级划入持有这一类别。请注意在上表中不包含非评级的股票。

此前的评级系统定义(直至2020年6月30日):

买入, 未来 12-18 个月内预期相对基准指数涨幅在 10%以上, 基准定义如下

中性, 未来 12-18 个月内预期相对基准指数变化不大,基准定义如下。根据 FINRA/NYSE 的评级分布规则, 我们会将中性评级划入持有这一类别。 卖出, 未来 12-18 个月内预期相对基准指数跌幅在 10%以上, 基准定义如下

各地股票基准指数:日本-TOPIX,韩国-KOSPI,台湾-TAIEX,印度-Nifty100;其他所有中国概念股-MSCI China.

Haitong International Equity Research Ratings Distribution, as of June 30, 2024

	Outperform	Neutral	Underperform	
		(hold)		
HTI Equity Research Coverage	91.4%	8.1%	0.6%	
IB clients*	3.1%	4.8%	0.0%	

^{*}Percentage of investment banking clients in each rating category.

BUY, Neutral, and SELL in the above distribution correspond to our current ratings of Outperform, Neutral, and Underperform. For purposes only of FINRA/NYSE ratings distribution rules, our Neutral rating falls into a hold rating category. Please note that stocks with an NR designation are

Previous rating system definitions (until 30 Jun 2020):

BUY: The stock's total return over the next 12-18 months is expected to exceed the return of its relevant broad market benchmark, as indicate: NEUTDAL. The steely's total return ever the poyt 12.19 menths is expected to be in line with the return of its relevant broad market benchmark, a

山州

弱干大市

prices based on possible valuation multiples. Such rankings or suggested prices do not purport to be stock ratings or target prices or fundamental values and are 海通国际 A 股覆盖:海通国际可能会就沪港通及深港通的中国 A 股进行覆盖及评级。海通证券(600837.CH),海通国际于上海的母公司,也会于中 是,海通国际使用与海通证券不同的评级系统,所以海通国际与海通证券的中国A股评级可能有所不同。

Haitong International Non-Rated Research: Haitong International publishes quantitative, screening or short reports which may rank stocks according to valuatio

Haitong International Coverage of A-Shares: Haitong International may cover and rate A-Shares that are subject to the Hong Kong Stock Connect scheme wit

Securities (HS; 600837 CH), the ultimate parent company of HTISG based in Shanghai, covers and publishes research on these same A-Shares for distribution in m system employed by HS differs from that used by HTI and as a result there may be a difference in the HTI and HS ratings for the same A-share stocks.

海通国际优质 100 A 股 (Q100) 指数: 海通国际 Q100 指数是一个包括 100 支由海通证券覆盖的优质中国 A 股的计量产品。这些股票是通过基于质量 6 股团队自下而上的研究。海通国际每季对 Q100 指数成分作出复审。 Haitong International Quality 100 A-share (Q100) Index: HTI's Q100 Index is a quant product that consists of 100 of the highest-quality A-shares under coverage carefully selected through a quality-based screening process in combination with a review of the HS A-share team's bottom-up research. The Q100 constituent co

盟浪义利 (FIN-ESG) 数据通免责声明条款:在使用盟浪义利 (FIN-ESG) 数据之前,请务必仔细阅读本条款并同意本声明:

成损失的, 由用户承担相应的赔偿责任, 盟浪不承担责任。

第一条 义利(FIN-ESG)数据系由盟浪可持续数字科技有限责任公司(以下简称"本公司")基于合法取得的公开信息评估而成,本公司对信息的准确性

的评估结果仅供参考,并不构成对任何个人或机构投资建议,也不能作为任何个人或机构购买、出售或持有相关金融产品的依据。本公司不对任何个 述的评估结果造成的任何直接或间接损失负责。

第二条 盟浪并不因收到此评估数据而将收件人视为客户,收件人使用此数据时应根据自身实际情况作出自我独立判断。本数据所载内容反映的是盟浪 断,盟浪有权在不发出通知的情况下更新、修订与发出其他与本数据所载内容不一致或有不同结论的数据。除非另行说明,本数据(如财务业绩数据

绩表现不作为日后回报的预测。 第三条 本数据版权归本公司所有,本公司依法保留各项权利。未经本公司事先书面许可授权,任何个人或机构不得将本数据中的评估结果用于任何营 改、复制、编译、汇编、再次编辑、改编、删减、缩写、节选、发行、出租、展览、表演、放映、广播、信息网络传播、摄制、增加图标及说明等。

第四条 如本免责声明未约定,而盟浪网站平台载明的其他协议内容(如《盟浪网站用户注册协议》《盟浪网用户服务(含认证)协议》《盟浪网隐和 协议的约定执行: 若本免责声明与其他协议约定存在冲突或不一致的,则以本免责声明约定为准。 SusallWave FIN-ESG Data Service Disclaimer: Please read these terms and conditions below carefully and confirm your agreement and acceptance with these te

ESG Data Service.

FIN-ESG Data is produced by SusallWave Digital Technology Co., Ltd. (In short, SusallWave)'s assessment based on legal publicly accessible information. S for any accuracy and completeness of the information. The assessment result is for reference only. It is not for any investment advice for any individual or instituti selling or holding any relative financial products. We will not be liable for any direct or indirect loss of any individual or institution as a result of using SusallWave

SusallWave do not consider recipients as customers for receiving these data. When using the data, recipients shall make your own independent judgment ac status. The contents of the data reflect the judgment of us only on the release day. We have right to update and amend the data and release other data that different conclusions without notification. Unless expressly stated, the data (e.g., financial performance data) represents p ast performance only and the past per prediction of future return.

can use these data for any profitable purpose. Besides, none of individual or institution can take actions such as amendment, replication, translation, compilat abbreviation, excerpts, issuance, rent, exhibition, performance, projection, broadcast, information network transmission, shooting, adding icons and instruction third-party is caused by those actions, users shall bear the corresponding compensation liability. SusallWave shall not be responsible for any loss. If any term is not contained in this disclaimer but written in other agreements on our website (e.g. User Registration Protocol of SusallWave Website, Use

The copyright of this data belongs to SusallWave, and we reserve all rights in accordance with the law. Without the prior written permission of our compar

Agreement of Susal/Wave Website, Privacy Policy of Susal/wave Website), it should be executed according to other agreements. If there is any difference between this disclaimer shall be applied.

重要免责声明: 非 **印度证券的研究报告:**本报告由海通国际证券集团有限公司("HTISGL")的全资附属公司海通国际研究有限公司("HTIRL")发行,该公司是根据香》 有第 4 类受规管活动(就证券提供意见)的持牌法团。该研究报告在 HTISGL 的全资附属公司 Haitong International (Japan) K.K. ("HTIJKK") 的协助下发行 可能会对投资产生不利影响。过去的表现并不一定代表将来的结果。某些特定交易,包括设计金融衍生工具的,有产生重大风险的可能性,因此并不过 本文件中的建议并非为您量身定制。分析师并未考虑到您自身的财务情况,如您的财务状况和风险偏好。因此您必须自行分析并在适用的情况下咨询自 其他方面的专业顾问,以期在投资之前评估该项建议是否适合于您。若由于使用本文件所载的材料而产生任何直接或间接的损失,HTISG 及其董事、A

不应被解释为对证券买卖的明示或暗示地出价或征价。在某些司法管辖区,本文件中提及的证券可能无法进行买卖。如果投资产品以投资者本国货币以

任。 除对本文内容承担责任的分析师除外,HTISG 及我们的关联公司、高级管理人员、董事和雇员,均可不时作为主事人就本文件所述的任何证券或衍生品 HTISG 的销售员、交易员和其他专业人士均可向 HTISG 的相关客户和公司提供与本文件所述意见相反的口头或书面市场评论意见或交易策略。HTISG T 一致的投资决策。但 HTIRL 没有义务来确保本文件的收件人了解到该等交易决定、思路或建议。

请访问海通国际网站www.equities.htisec.com,查阅更多有关海通国际为预防和避免利益冲突设立的组织和行政安排的内容信息。 非 美国分析师披露信息: 本项研究首页上列明的海通国际分析师并未在 FINRA 进行注册或者取得相应的资格,并且不受美国 FINRA 有关与本项研究目标 证券交易的第2241条规则之限制。

IMPORTANT DISCLAIMER

December 2016.

For research reports on non-Indian securities: The research report is issued by Haitong International Research Limited ("HTIRL"), a wholly owned subsidiary of Hai Limited ("HTISGL") and a licensed corporation to carry on Type 4 regulated activity (advising on securities) for the purpose of the Securities and Futures Ordinance assistance of Haitong International (Japan) K.K. ("HTIJKK"), a wholly owned subsidiary of HTISGL and which is regulated as an Investment Adviser by the Kanto Fin For research reports on Indian securities: The research report is issued by Haitong Securities India Private Limited ("HSIPL"), an Indian company and a Securities and registered Stock Broker. Merchant Banker and Research Analyst that, inter alia, produces and distributes research reports covering listed entities on the BSE Li m

Exchange of India Limited ("NSE") (collectively referred to as "Indian Exchanges"). HSIPL was acquired and became part of the Haitong International Securities GI

All the research reports are globally branded under the name Haitong International and approved for distribution by Haitong International Securities Company L members within HTISG in their respective jurisdictions. The information and opinions contained in this research report have been compiled or arrived at from sources believed to be reliable and in good faith but no rep implied, is made by HTIRL, HTISCL, HSIPL, HTIJKK or any other members within HTISG from which this research report may be rec eived, as to their accuracy, compli-

expressed herein are as of the date of this research report and are subject to change without notice. This research report is for information purpose only. Des securities mentioned herein are not intended to be complete and this research report is not, and should not be construed expressly or impliedly as, an offer to be referred to in this research report may not be eligible for purchase or sale in some jurisdictions. If an investment product is denominated in a currency other t change in exchange rates may adversely affect the investment. Past performance is not necessarily indicative of future result s. Certain transactions, including tho substantial risk and are not suitable for all investors. You should also bear in mind that recommendations in this research report are not tailor-made for you. The

your unique financial circumstances, such as your financial situation and risk appetite. You must, therefore, analyze and should, where applicable, consult your of and other professional advisers to evaluate whether the recommendations suits you before investment. Neither HTISG nor any of its directors, employees or agei for any direct or consequential loss arising from any use of the materials contained in this research report.

HTISG and our affiliates, officers, directors, and employees, excluding the analysts responsible for the content of this document, will from time to time have long o in, and buy or sell, the securities or derivatives, if any, referred to in this research report. Sales, traders, and other professionals of HTISG may provide oral or writ strategies to the relevant clients and the companies within HTISG that reflect opinions that are contrary to the opinions expressed in this research report. HTISG m are inconsistent with the recommendations or views expressed in this research report. HTI is under no obligation to ensure that such other trading decisions, idea

to the attention of any recipient of this research report. Please refer to HTI's website www.equities.htisec.com for further information on HTI's organizational and administrative arrangements setup for the prevention a with respect to Research.

Non U.S. Analyst Disclosure: The HTI analyst(s) listed on the cover of this Research is (are) not registered or qualified as a research analyst with FINRA and are r restrictions on communications with companies that are the subject of the Research; public appearances; and trading securities by a research analyst.

分发和地区通知:

除非下文另有规定,否则任何希望讨论本报告或者就本项研究中讨论的任何证券进行任何交易的收件人均应联系其所在国家或地区的海通国际销售人员 **香港投資者的通知事項:**海通国际证券股份有限公司("HTISCL")负责分发该研究报告,HTISCL 是在香港有权实施第 1 类受规管活动(从事证券交易)的 《证券及期货条例》(香港法例第 571 章)(以下简称"SFO")所界定的要约邀请,证券要约或公众要约。本研究报告仅提供给 SFO 所界定的"专业投

期货事务监察委员会的审查。您不应仅根据本研究报告中所载的信息做出投资决定。本研究报告的收件人就研究报告中产生或与之相关的任何事宜请耶

关金融工具的交易。本研究报告中出现的 HSIPL,HTIRL 或 HTIJKK 分析师没有注册或具备 FINRA 的研究分析师资格,因此可能不受 FINRA 第 2241 条规》 和分析师账户持有的交易证券等限制。投资本研究报告中讨论的任何非美国证券或相关金融工具(包括 ADR)可能存在一定风险。非美国发行的证券可 约束。有关非美国证券或相关金融工具的信息可能有限制。外国公司可能不受审计和汇报的标准以及与美国境内生效相符的监管要求。本研究报告中以 证券或相关金融工具的投资或收益的价值受汇率波动的影响,可能对该等证券或相关金融工具的价值或收入产生正面或负面影响。美国收件人的所有问

Haitong International Securities (USA) Inc.

340 Madison Avenue, 12th Floor

联系人电话: (212)3516050

New York, NY 10173

DISTRIBUTION AND REGIONAL NOTICES Except as otherwise indicated below, any Recipient wishing to discuss this research report or effect any transaction in any s ecurity discussed in HTI's research shou salesperson in their own country or region.

Inc. ("HTI USA"), located at 340 Madison Avenue, 12th Floor, New York, NY 10173, USA; telephone (212) 351 6050. HTI USA is a broker-dealer registered in tl

report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income

Notice to Hong Kong investors: The research report is distributed by Haitong International Securities Company Limited ("HTISCL"), which is a licensed corpor ation

(dealing in securities) in Hong Kong. This research report does not constitute a solicitation or an offer of securities or an invitation to the public within the meani is only to be circulated to "Professional Investors" as defined in the SFO. This research report has not been reviewe d by the Securities and Futures Commission

decisions solely on the basis of the information contained in this research report. Recipients of this research report are to contact HTISCL salespersons in respec

connection with, the research report.

Notice to U.S. investors: As described above, this research report was prepared by HTIRL, HSIPL or HTIJKK. Neither HTIRL, HSIPL, HTIJKK, nor any of the non U.S.

United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research

"major U.S. institutional investors" and "U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities

When distributing research reports to "U.S. institutional investors," HTI USA will accept the responsibilities for the content of the reports. Any U.S. recipient of the any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Hai

Exchange Commission (the "SEC") and a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"). HTI USA is not responsible for the preparation analysis contained therein. Under no circumstances should any U.S. recipient of this research report contact the analyst directly or effect any transaction to buy or instruments directly through HSIPL, HTIRL or HTIJKK. The HSIPL, HTIRL or HTIJKK analyst(s) whose name appears in this research report is not registered or qualifi

and, therefore, may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. or be subject to U.S. regulations. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject and regulatory requirements comparable to those in effect within the U.S. The value of any investment or income from any securities or related financial ins

financial instruments. All inquiries by U.S. recipients should be directed to: Haitong International Securities (USA) Inc. 340 Madison Avenue, 12th Floor

New York, NY 10173 Attn: Sales Desk at (212) 351 6050

中华人民共和国的通知事项:在中华人民共和国(下称"中国",就本报告目的而言,不包括香港特别行政区、澳门特别行政区和台湾)只有根据适用6

员方可使用该材料。并且根据相关法律法规,该材料中的信息并不构成"在中国从事生产、经营活动"。本文件在中国并不构成相关证券的公共发售或讠 何规定,在取得中国政府所有的批准或许可之前,任何法人或自然人均不得直接或间接地购买本材料中的任何证券或任何实益权益。接收本文件的人员 **加拿大投资者的通知事项:**在任何情况下该等材料均不得被解释为在任何加拿大的司法管辖区内出售证券的要约或认购证券的要约邀请。本材料中所

售行为均只能在豁免向有关加拿大证券监管机构提交招股说明书的前提下由 Haitong International Securities (USA) Inc. ("HTI USA")予以实施,该公司是 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations ("NI 31-103") 的规定得到 「国际交易商豁免」("International Dealer Exe 省、不列颠哥伦比亚省、安大略省和魁北克省。在加拿大,该等材料在任何情况下均不得被解释为任何证券的招股说明书、发行备忘录、广告或公开外

类似的监管机构均未审查或以任何方式批准该等材料、其中所载的信息或所述证券的优点,任何与此相反的声明即属违法。在收到该等材料时,每个 National Instrument 45-106 Prospectus Exemptions 第 1.1 节或者 Securities Act (Ontario)第 73.3(1)节所规定的「认可投资者」("Accredited Investor"

Instrument 31-103 第 1.1 节所规定的「许可投资者」("Permitted Investor")。

电话: (65) 6713 0473

日本投資者的通知事項:本研究报告由海通国际证券有限公司所发布,旨在分发给从事投资管理的金融服务提供商或注册金融机构(根据日本金融 (1) 条, 第 17-11 (1) 条的执行及相关条款)。

英国及欧盟投资者的通知事项:本报告由从事投资顾问的 Haitong International Securities Company Limited 所发布,本报告只面向有投资相关经验的专业

相关的投资行为只面对此类专业客户。没有投资经验或相关投资经验的客户不得依赖本报告。Haitong International Securities Company Limited 的分支机

超过本研究报告中提及的实体已发行股本总额的 0.5%。特别提醒有些英文报告有可能此前已经通过中文或其它语言完成发布。

溴 大利亚投资者的通知事项: Haitong International Securities (Singapore) Pte Ltd, Haitong International Securities Company Limited 和 Haitong International:

大利亚证券和投资委员会(以下简称"ASIC")公司(废除及过度性)文书第 2016/396 号规章在澳大利亚分发本项研究,该等规章免除了根据 2001 年 提供金融服务时海通国际需持有澳大利亚金融服务许可的要求。ASIC 的规章副本可在以下网站获取:www.legislation.gov.au。海通国际提供的金融服务

等法律与在澳大利亚所适用的法律存在差异。 **印度投资者的通知事项:** 本报告由从事证券交易、投资银行及证券分析及受 Securities and Exchange Board of India("SEBI")监管的 Haitong Securities Ir 发布,包括制作及发布涵盖 BSE Limited("BSE")和 National Stock Exchange of India Limited("NSE")(统称为 「印度交易所」)研究报告。

研究机构名称: Haitong Securities India Private Limited

SEBI 研究分析师注册号: INH000002590 地址: 1203A, Floor 12A, Tower 2A, One World Center

841 Senapati Bapat Marg, Elphinstone Road, Mumbai 400 013, India

CIN U74140MH2011FTC224070

电话:+91 22 43156800 传真:+91 22 24216327

合规和申诉办公室联系人: Prasanna Chandwaskar; 电话:+91 22 43156803; 电子邮箱:prasanna.chandwaskar@htisec.com "请注意. SEBI 授予的注册和 NISM 的认证并不保证中介的表现或为投资者提供任何回报保证"。

本项研究仅供收件人使用、未经海通国际的书面同意不得予以复制和再次分发。

版权所有:海通国际证券集团有限公司 2019年。保留所有权利。

People's Republic of China (PRC): In the PRC, the research report is directed for the sole use of those who receive the research report in accordance with the a Further, the information on the research report does not constitute "production and business activities in the PRC" under relevant PRC laws. This research report

of the security, whether by sale or subscription, in the PRC. Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the security without obtaining all prior PRC government approvals or licenses that are required, whether statutorily or otherwise. Persons who come into possession of th

these restrictions. Notice to Canadian Investors: Under no circumstances is this research report to be construed as an offer to sell securities or as a solicitation of an offer to buy sec

Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant only by Haitong International Securities (USA) Inc., a dealer relying on the "international dealer exemption" under National Instrument 31-103 Registration Requ

Registrant Obligations ("NI 31-103") in Alberta, British Columbia, Ontario and Quebec. This research report is not, and under no circumstances should be cons memorandum, an advertisement or a public offering of any securities in Canada. No securities commission or similar regulatory authority in Canada has review research report, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. Upon re Canadian recipient will be deemed to have represented that the investor is an "accredited investor" as such term is defined in section 1.1 of National Instrument

in Ontario, in section 73.3(1) of the Securities Act (Ontario), as applicable, and a "permitted client" as such term is defined in section 1.1 of NI 31-103, respectivel Notice to Singapore investors: This research report is provided in Singapore by or through Haitong International Securities (Singapore) Pte Ltd ("HTISSPL"). HTIS under the Financial Advisers Act 2001 ("FAA") to (a) advise on securities, units in a collective investment scheme, exchange-traded derivatives contracts and ove and (b) issue or promulgate research analyses or research reports on securities, exchange -traded derivatives contracts and over-the-counter derivatives contracts.

to institutional investors, within the meaning of Section 4A of the Securities and Futures Act 2001. Recipients of this research report are to contact HTISSPL via

matters arising from, or in connection with, the research report: Haitong International Securities (Singapore) Pte. Ltd.

10 Collyer Quay, #19-01 - #19-05 Ocean Financial Centre, Singapore 049315

Talanhana, (CE) C712 0472

Persons who do not have professional experience in matters relating to investments should not rely on this research. Haitong International Securities Company long or short financial interest in excess of 0.5% of the total issued share capital of the entities mentioned in this research report. Please be aware that any report previously in Chinese or another language.

Notice to Australian investors: The research report is distributed in Australia by Haitong International Securities (Singapore) Pte Ltd, Haitong International Securities

International Securities (UK) Limited in reliance on ASIC Corporations (Repeal and Transitional) Instrument 2016/396, which exempts those HTISG entities from the financial services license under the Corporations Act 2001 in respect of the financial services it provides to wholesale clients in Australia. A copy of the ASIC C following website, www.legislation.gov.au. Financial services provided by Haitong International Securities (Singapore) Pte Ltd, Haitong International Securities

International Securities (UK) Limited are regulated under foreign laws and regulatory requirements, which are different from the laws applying in Austra lia. Notice to Indian investors: The research report is distributed by Haitong Securities India Private Limited ("HSIPL"), an Indian company and a Securities and Exchange Stock Broker, Merchant Banker and Research Analyst that, inter alia, produces and distributes research reports covering listed entities on the BSE Limited ("BSE")

Name of the entity: Haitong Securities India Private Limited

India Limited ("NSE") (collectively referred to as "Indian Exchanges").

SEBI Research Analyst Registration Number: INH000002590

Address: 1203A. Floor 12A. Tower 2A. One World Center

841 Senapati Bapat Marg, Elphinstone Road, Mumbai 400 013, India

CIN U74140MH2011FTC224070

Ph: +91 22 43156800 Fax:+91 22 24216327

Details of the Compliance Officer and Grievance Officer: Prasanna Chandwaskar: Ph: +91 22 43156803; Email id: prasanna.chandwaskar@htisec.com

"Please note that Registration granted by SEBI and Certification from NISM in no way guarantee performance of the intermediary or provide any assurance of ret

This research report is intended for the recipients only and may not be reproduced or redistributed without the written consent of an authorized signatory of HTI Copyright: Haitong International Securities Group Limited 2019. All rights reserved.

http://equities.htisec.com/x/legal.html

Luxi Chemical Group - 000830 CH



6 May 2022 OUTPERFORM at 18.20 target 20.81.